Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Announces Auditor Not Standing for Re-Appointment

Apr 23, 2025 5:00pm EDT

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 23, 2025 7:30am EDT

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Apr 01, 2025 8:30am EDT

Aptose Reports Year End 2024 Results and Corporate Highlights

Mar 28, 2025 8:01am EDT

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Mar 17, 2025 7:30am EDT

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Feb 20, 2025 7:32am EST

Aptose Announces Reverse Share Split

Feb 18, 2025 4:30pm EST

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Feb 13, 2025 4:30pm EST

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Feb 12, 2025 7:00am EST

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Jan 09, 2025 4:00pm EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...33
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences